CDKN1A and neuroblastoma: We found dose-dependent upregulation of CDKN1A in both TP53-mutated (SK-N-BE(2)-C, Fig. 4f) and TP53-wild type neuroblastoma cells (IMR-32, Fig. 4g) after 72 h of TH34 treatment.